Individualization of approaches to managing patients during menopausal transition
Keywords:menopause, individual therapy, MHT, estrogens, gestogens, levonorgestrel
The global aging of the population leads to a significant increase in the demographic burden on society, puts a heavy burden on the economy and causes significant structural changes in the sphere of social security. Therefore, the problem of maintaining the health of women in peri- and post-menopause becomes extremely important for public health and health. It is in this period that a number of somatic and mental diseases appear that significantly affect the quality and overall life span of a woman. Inevitably, menopausal manifestations is a change in hormone levels that causes various symptoms, including vasomotor disorders, bone density, hair loss, decreased sexual interest and mood, etc. Therefore, the development of therapeutic and rehabilitative programs for women of menopausal age, based on pathogenetically substantiated complex treatment. Among other things, patients in the phase of the menopausal transition need to take into account several principal provisions:
– Clinical deficiency of sex hormones (estrogens, progesterone and testosterone) in women is an indication for the appointment of menopausal hormone therapy (MHT) with appropriate hormones. This should be done as soon as possible (during the menopausal transition) and personified – taking into account the individual characteristics of patients. The purpose of MHT should correspond to the symptomatology and goals of the prevention of various diseases, as well as the history, research results, preferences and expectations of women.
– Women who need correction of the symptoms of menopause and adequate control of the endometrium, should be prescribed a combination of estrogen and gestogen. In the presence of risk factors for hyperproliferation, the best choice is the combination of estrogen and progestogens with antiproliferative activity, for example levonorgestrel, which can be prescribed both in combination menopausal therapy and in the form of an intrauterine system with this gestogen.
– A special category is patients who have clinical manifestations of androgen deficiency in the clinical situation, in addition to the characteristic symptoms of estrogen deficiency. In such patients, preference should be given to the drug containing levonorgestrel, which has residual androgenic activity, provides adequate control of the endometrium and has additional advantages with regard to the prevention of osteoporosis, premature ovarian failure and cognitive decline.
- United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP/248.
- Diczfalusy, E. “Ageing: a medical, social and ethical challenge.” IV European Congress on Menopause. Edition ESKA (1998): 655–67.
- Goncharov, N.N., Katsia, G.V., Melikhova, O.A., et al. “Androgenic deficiency in women and the possibility of its hormonal diagnosis.” Problems of endocrinology 3 (2011): 31–6.
- Yureneva, S.V., Ilyina, L.M., Smetnik, V.P. “Aging of the Reproductive System of Women: From Theory to Clinical Practice.” Obstetrics and gynecology 3 (2014): 21–7.
- Bromberger, J.T., Kravitz, H.M. “Mood and Menopause: Findings from the Study of Women’s Health Across the Nation (SWAN) over ten years.” Obstet Gynecol Clin North Am 38.3 (2011): 609–25.
- Cohen, L.S., Soares, C.N., Vitonis, A.F., et al. “Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles.” Arch Gen Psychiatry 63 (2006): 385–90.
- de Kruif, M., Spijker, A.T., Molendjak, M.L. “Depression during the perimenopause: A meta-analysis.” J of Affective Disorders 206 (2016): 174–80.
- Wigg, C. “A Brief Review of Neuropsychic Symptoms Associated with the Female Climacteric: Depression and Mental Health.” J Neurol Stroke 7.4: 00248. DOI: 10.15406/jnsk.2017.07.00248
- Lowenstein, L., Shechter, A., Porst, H., et al. “Physicians’ attitudes towards androgen replacement therapy for male and female sexual dysfunction.” Int J Impot Res 28.2 (2016): 57–60.
- Davis, S.R., Wahlin-Jacobsen, S. “Testosterone in women – the clinicalsignificance.” Lancet Diabetes Endocrinol 3.12 (2015): 980–92.
- Fonseca, H.P., Scapinelli, A., Aoki, T., Aldrighi, J.M. “Androgen deficiency in women.” Rev Assoc Med Bras 56.5 (2010): 579–82.
- Tapilskaya, N.I., Khamoshina, M.B., Shestakova, I.G. “Personalized approach to hormonal therapy for premature ovarian failure and during the menopausal transition.” Doktor.Ru 8.125–9.126 (2016): 47–51.
- Khamoshina, M.B., Bril. Y.A. Menopausal disorders: variability of therapeutic approaches. Moscow. Editorial board of the StatusPraesens Journal (2014): 20 p.
- Tyuzikov, I.A., Kalinichenko, S.Y., Apetov, S.S. “Androgen deficiency in women in urogynecological practice: pathophysiology, clinical «masks» and pharmacotherapy with the use of transdermal forms of testosterone.” Russian Bulletin of the Obstetrician-Gynecologist 1 (2014): 33–43.
- Van Voorhis, B.J., Santoro, N., Harlow, S., et al. “The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause.” Obstet Gynecol 112.1 (2008): 101–8.
- Phillips, V., Graham, C.T., Manek, S., McCluggage, W.G. “The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology.” J Clin Pathol 56 (2003): 305–7.
- Archer, D.F. “Endometrial bleeding during hormone therapy: the effect of progestogens.” Maturitas 57.1 (2007): 71–6.
- Trabert, B., Wentzensen, N., Yang, H.P., et al. “Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?” Int J Cancer 132.2 (2013): 417–26.
- Kuznetsova, I.V., Tikhonovskaya, I.V. “Menopausal hormonal therapy in perimenopausal women with abnormal maternal bleedings.” Doktor.Ru 3.120 (2016): 25–9.
- Tatarchuk, T.F., Kosei, N.V., Tutchenko, T.M. “Early ovarian failure: syndrome or diagnosis.” Reproductive Endocrinology 2.34 (2017).
- Butovskaya, O.N. A differentiated choice of HRT in late reproductive age. Thesis abstract for PhD degree. Moscow (2006).
- Albright, F., Smith, P., Fraser, R. “A syndrome characterized by primary ovarian insufficiency and decreased stature.” Am J Med Sci 204 (1942): 625–48.
- Webber, L., et al. “ESHRE Guideline: management of women with premature ovarian insufficiency.” Human Reproduction 31.5 (2016): 926–37.
- Baber, R.J., Panay, N., Fenton, A.; The IMS Writing Group. “2016 IMS Recommendations on women’s midlife health and menopause hormone therapy.” Climacteric 19 (2016): 109–50.
- Tatarchuk, T.F., Islamova, A.O., Yefymenko, O.O. “Climacteric syndrome as the first clinical manifestation of perimenopause.” Reproductive Endocrinology 1.21 (2015).
- National consensus on the management of patients in the climacteric. Reproductive endocrinology 1.21 (2016).
- Smetnik, V.P. “Premature menopause.” The attending physician 10 (2004).
- The North American Menopause Society. “The 2017 hormone therapy position statement of The North American Menopause Society.” Menopause 24.7 (2017): 728–53.
- Kaufman, J.M. “Pharmakokinetiks of oestrogens and hormone replasment therapy.” Eur J Menopause 4 (1997): 14–22.
How to Cite
Copyright (c) 2018 Т. Ф Татарчук, В. І. Пирогова, О. О. Єфіменко, О. В. Булавенко, І. М. Антонян, Г. Я. Пілягіна
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.